PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15610697

Stem cells: implications for urology.

Kirk C Lo·Shannon Whirledge·Dolores J Lamb
View original source ↗Export metadata ↓

Abstract

Stem cells are characterized by their potential immortality and are capable of self-renewal and differentiation. Stem cells are proposed to provide the potential to cure degenerative diseases and to give important clues regarding human development and aging. However, stem cell research has evoked enthusiasm and passionate debate regarding the ethics of their use in medicine and reproduction. In this article, the current understanding of the biology of stem cells, their application in urology, and some of the controversies regarding their use are discussed. Although the clinical application of stem cell technologies to urologic practice is likely to be well in the future, advances in this field hold great promise for the correction of a number of illnesses. Nevertheless, scientists and ethicists will continue to struggle with their ethical responsibilities to the patient and society.

Explore related subjects

Biomedical ResearchEmbryo ResearchEthics, ResearchForecastingHumansInfertility, MaleMaleRisk AssessmentStem Cell TransplantationTissue EngineeringTreatment OutcomeUrologyJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kirk C Lo, Shannon Whirledge, Dolores J Lamb. 2005. Stem cells: implications for urology.. https://doi.org/10.1007/s11934-005-0067-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.

Progress in the care of patients with leukemia has been one of the great success stories in the field of oncology, and clinical research in leukemia has been the "flagship" of the Cancer and Leukemia Group B since the inception of this organization. Lessons learned from the founders' emphasis on childhood and adult leukemia have been extended broadly over the past 50 years to virtually all types of malignant diseases, and the Leukemia Committee has continued to provide leadership and key contributions. The Leukemia Committee is focused on the individualization of treatment based on distinctive biological and clinical characteristics with the aim of increasing efficacy and decreasing nonspecific toxicity. Our clinical trials in leukemia and myeloma have shifted from primarily empirically derived comparisons of different chemotherapeutic regimens to testing novel concepts such as the role of dose intensity, inhibition of specific mechanisms of drug resistance, the use of hematopoietic growth factors and monoclonal antibodies, and the utility of targeted agents. The Cancer and Leukemia Group B was the pioneer among the cooperative groups in the creation of centralized tissue repositories and the incorporation of correlative laboratory studies as an integral feature of clinical trials, a practice now termed "translational research." Considerable effort has focused on the identification of important pretreatment characteristics, such as morphologic features, immunophenotype, chromosomal abnormalities, and molecular defects, which are significantly associated with outcome in multivariable analyses and which enhance our understanding for the complex biology of these diseases.

Biomedical Research↗